EMA Authorised: Imaavy (nipocalimab) — Janssen Cilag International NV

View source ↗

Summary

The European Medicines Agency has authorised Imaavy (nipocalimab) for the treatment of myasthenia gravis, on behalf of Janssen Cilag International NV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• IMAAVY (NIPOCALIMAB)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis. MAH: Janssen Cilag International NV. Decision date: 28/11/2025